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Abstract
Background: Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS)
and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information
regarding blood transcriptional changes induced by IFN treatment in SPMS patients is available. Our aim was to
identify a subgroup of SPMS patients presenting a gene expression signature similar to that of RRMS patients who
are clinical responders to IFN treatment.
Methods: SPMS patients (n = 50, 20 IFN treated and 30 untreated) were classified using unsupervised hierarchical
clustering according to IFN inducible gene expression profile identified in RRMS clinical responders to treatment.
IFN inducible gene expression profile was determined by finding differentially expressed genes (DEGs) between IFN
treated (n = 10) and untreated (n = 25) RRMS patients. Validation was performed on an additional independent
group of 27 SPMS IFN treated patients by qRT-PCR.
Results: One hundred and four DEGs, enriched by IFN signaling pathway (p = 7.4E-08), were identified in IFN treated
RRMS patients. Classification of SPMS patients based on these DEGs yielded two patient groups: (1) IFN transcriptional
responders (n = 12, 60 % of SPMS treated patients) showing gene-expression profile similar to IFN treated RRMS patients;
(2) IFN transcriptional non-responders (n= 8) showing expression profile similar to untreated patients. IFN transcriptional
responders were characterized by a more active disease, as defined by higher EDSS progression and annual relapse rate.
Conclusion: Within the IFN treated SPMS population, 60 % of patients have a transcriptional response to IFN which is
similar to that of RRMS patients who are IFN responders to treatment.
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Background
Secondary progressive (SP) multiple sclerosis (MS) is the
progressive phase of relapsing remitting (RR) disease
characterized by a shift to continuous accumulation of
neurological damage, with or without occasional relapses
or minor remissions [1].
As MS progresses from the RR to SP stage, a shift also
occurs in the underlying disease pathogenesis. This shift
reflects a change from a predominantly autoimmune dis-
ease process to one with both inflammatory and neurode-
generative elements [2]. Neurodegenerative components
have been demonstrated in pathological and imaging stud-
ies by documenting axonal injury in areas devoid of
inflammatory response including normal appearing
white and grey matter, as well as generalized brain at-
rophy [3, 4]. The increased importance of neurodegener-
ation in SP is one possible explanation as to why some
disease modifying immunomodulatory therapies (IMD),
which are effective in RRMS, lose their efficacy later on
[5]. However, evidence derived from pathological examin-
ation of brains has shown that neurodegenerative pro-
cesses are dependent on an ongoing inflammatory activity
as demonstrated by coexistence of neurodegeneration and
inflammatory infiltrates, including active T and B cells [6].* Correspondence: Michael.Gurevich@sheba.health.gov.il
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Currently, interferon (IFN) beta-1b is the only immu-
nomodulatory treatment approved for use in SPMS pa-
tients. However, the two main clinical trials, the
European [7] and North American [8] trials, which ex-
amined the efficacy of this treatment, have shown diver-
gent results [7–9]. The European trial has shown IFN
beta-1b delayed progression of disability whereas in the
American trial this finding was not replicated. These
contradictory results have subsequently been attributed
to differing clinical characteristics of patients enrolled in
trials, with better treatment outcome associated with pa-
tients at an earlier, more active stage of disease as dem-
onstrated by shorter disease duration and higher relapse
rate prior to trial initiation [9]. As there is a heteroge-
neous clinical response to treatment in SPMS, it is im-
portant to discover biomarkers which can help identify
those patients who could benefit most from therapy.
Gene expression of immunocompetent cells provides a
direct representation of disease mechanisms in play.
Whereas treatment effects, seen clinically or on MRI,
take a long time to evolve, changes on the molecular
level are evident much sooner [10, 11]. The gene expres-
sion effects of IFN treatment have been well character-
ized in immunocompetent cells obtained from RRMS
patients [11, 12]. These effects, consistently and repeat-
edly replicated, have become widely accepted as the
"IFN signature" [13, 14]. Although the precise mechan-
ism, by which IFN treatment exerts benefit in RRMS, is
unknown, this "IFN signature" affects biological path-
ways related to antiviral activity, immune-regulation, cell
survival and apoptosis, cell cycle control, and transcrip-
tion regulation [15]. Specific interferon inducible genes
have been identified that correlate with a better clinical
response to IFN treatment in RRMS patients [16, 17], in
addition it has been shown that pre-treatment baseline
levels of IFN- inducible genes are predictive of clinical
response to treatment - with a low expression of IFN in-
duced genes prior to treatment associated with better
clinical response [18, 19]. In SPMS, transcriptional stud-
ies are much sparser than in RRMS. Studies have exam-
ined differences in signatures between non treated
SPMS compared to RRMS patients, and have shown
minor differences between MS subgroups [20]. However,
no transcriptomic studies, regarding blood transcrip-
tional changes induced by IFN treatment in SPMS pa-
tients, are currently available.
We suggest that within the SPMS population some pa-
tients have RRMS like inflammatory components tar-
geted by IFN. Therefore, the objective of the current
study was to find a subgroup of IFN treated SPMS pa-
tients, presenting a gene expression signature similar to
that of clinical responders to IFN treated RRMS patients.
This information could be used to assist in clinical deci-
sion making regarding continuation of IFN treatment in




This study is a retrospective exploratory study in which
interferon treatment induced gene expression signatures
in clinically responding relapsing remitting MS patients
were used to classify secondary progressive multiple
sclerosis patients undergoing IFN treatment. Peripheral
blood mononuclear cells (PBMC) were collected from
RRMS and SPMS patients. Demographic and clinical
characteristics of patients are presented in Table 1. All
patients were diagnosed according to McDonald's 2010
diagnostic criteria [21].
First, in order to obtain a gene expression profile asso-
ciated with good clinical response to treatment, an IFN
inducible transcriptional profile was determined. This
was achieved by identifying differentially expressed genes
(DEGs), between clinically responsive IFN treated and
untreated RRMS patients. We specifically chose to com-
pare RRMS patients who were clinically responsive to
IFN treatment, with RRMS patients who were untreated.
This approach, unlike comparing treatment responders
vs. non-responders, enabled us to evaluate the character-
istic signature of changes in gene expression profile,
which were triggered by exposure to interferon in the
responding patients.
Inclusion criteria for RRMS patients were: (a) Ex-
tended disability status score (EDSS) < = 4.5; (b) IFN
treatment for at least 4 months prior to study initiation;
(c) Good response to IFN treatment, defined as no acute
relapse and no progression in disability during the fol-
lowing 2 years of treatment.
Next, SPMS patients were classified, using unsuper-
vised hierarchal clustering, based on RRMS IFN induced
transcriptional profile. Verification of findings was per-
formed on an additional independent group of IFN
treated SPMS patients. Inclusion criteria for SPMS pa-
tients were: (a) EDSS > = 5.0; (b) EDSS progression by at
least 1 point during the 2 years preceding the study; (c)
IFN treatment for at least 2 years prior to study initi-
ation. Study design is shown in Fig. 1.
Table 1 Demographical and clinical characteristics of patients
Groups RRMS SPMS
N 35 50
Mean age (years)* 40.2 ± 1.2 52.2 ± 1.1
F (M) 20 (15) 34 (16)
IFN treated (untreated) 10 (25) 20 (30)
Mean EDSS* 2.2 ± 0.2 6.8 ± 0.1
Mean disease duration (years)* 6.8 ± 0.8 18.1 ± 1.4
*p-value <0.05
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All patients were steroid free and untreated patients
were also IMD treatment free for at least 30 days prior to
blood sampling. Treated patients received IFN-beta-1a
(Rebif new formulation Merck-Serono), at a dose of 22 or
44 mcg, administered subcutaneously 3 times per week.
Microarray preparation
Total RNA from PBMC was extracted using Trizol (Invi-
trogen, USA) and Phase-Look-Gel columns (Eppendorf,
Germany). RNA quality was determined by BioRad
Experion automatic electrophoresis station. cDNA was syn-
thesized using the One-Cycle cDNA Synthesis Kit, and
transcribed by GeneChip IVT Labeling Kit (Affymetrix,
Inc. CA.), and hybridized to HGU133A or HGU133A-2 mi-
croarrays, washed in a GeneChip Fluidics Station 450 and
scanned on GeneArray-TM scanner (G2500A, Hewlett
Packard) according to Affymetrix Inc protocol.
Data pretreatment, normalization and statistical analysis
Microarray data was normalized by R Bioconductor
Packages [22] as follows: a) arrays were normalized using
single-sample microarray normalization [23]; b) Batch
effect was treated by Combat SVA package [24]. Partek
Genomics Software was used for statistical analysis. Dif-
ferentially expressed genes (DEGs) were determined
using p-value cut off <0.05 after Bonferroni correction
for multiple comparisons.
DEG's were applied for functional analysis using QIA-
GEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity). Significantly
enriched pathways passed threshold of p < 0.05 after
Benjamini-Hochberg correction. Classification of SPMS
patients was done by unsupervised hierarchical cluster-
ing using Euclidean dissimilarity and average linkage al-
gorithm. All continuous parameters including patient
clinical and demographical characteristics are presented
by mean ± standard error.
IFN neutralizing antibody (NAB) testing
Quantifying of NAB, in serum samples of IFN treated
SPMS patients, was performed after two years of treatment
according to a method described by Bertolotto et al. [25].
Verification of key IFN inducible genes
cDNA was prepared using 1 μg of the total RNA as tem-
plate with AMV Reverse Transcription System (Promega,
USA). In order to determine mRNA expression, real-time
quantitative reverse-transcription-PCR (qRT-PCR) was
performed using TaqMan technology (Applied Biosystems,
USA). HPRT1 mRNA levels were measured as internal
control to normalize for mRNA input. The differences be-
tween patient groups were assessed using T – test statistic.
Significance level was defined as p < 0.05.
Ethics, consent and permissions
This study was approved by the Sheba Medical Center
Institutional Review and Ethical Board; all patients gave
written informed consent.
Fig. 1 Study design
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Availability of supporting data
The data set supporting the results of this article, includ-
ing all raw and processed microarray data and patient
parameter metadata, is available in the GEO omnibus,
accession number GSE73608.
Results
IFN inducible transcriptional profile associated with good
clinical response to treatment in RRMS patients
IFN treated RRMS patients with good clinical response
to treatment (n = 10, mean age 40.9 ± 2.3 years, 4 fe-
males, disease duration 5.9 ± 1.5 years, EDSS 1.6 ± 0.4),
were compared to untreated RRMS patients (n = 25, age
38.1 ± 1.0 years, 16 females, disease duration 7.2 ±
1.1 years, EDSS 2.4 ± 0.2). No statistically significant dif-
ferences existed between untreated and treated RRMS
patients in relation to age, gender, EDSS and disease
duration at time of blood sampling. IFN treated RRMS
patients exhibited no disease progression, with a nega-
tive average change in EDSS of −0.3 ± 0.2 points and no
relapses after two years of treatment.
Differential gene expression analysis yielded 104
DEG's, of which 87 were over-expressed and 17 under-
expressed (Fig. 2a). A complete list of DEG’s is available
in Additional file 1: Table S1. Examining enrichment of
these DEGs, using Ingenuity database, showed high en-
richment level for IFN type 1 pathway (p = 1.7E-16), spe-
cifically for IFN beta signaling (p = 7.4E-08). According
to Ingenuity database, 50 of 104 DEGs are known inter-
feron inducible genes. Amongst these genes, those exhi-
biting the greatest fold change (2.9-1.8 log2 fold change)
include IFN inducible genes such as: IFI44L, IFIT1,
IFI44, IFIT3, MX1, ISG15, SIGLEC1, OAS3, and OAS1
genes. Figure 2b demonstrates key DEGs involved in the
canonical IFN beta signaling pathway.
Transcriptional profile distinguishing between untreated
SPMS and RRMS patients
SPMS untreated patients (n = 30, mean age 51.3 ± 1.4 years,
17 females, disease duration 19.5 ± 1.4 years, EDSS 7.1 ±
0.1) were compared to RRMS untreated patients. We
found 147 DEGs, of which 131 were under expressed and
16 were over expressed among SPMS patients. A complete
list of DEGs is available in Additional file 2: Table S2.
These DEGs were characterized by enrichment of genes
which are associated with suppression of inflammatory
processes in SPMS patients, as demonstrated by decreased
immune response of leukocytes (p-value 1.3E-02), and de-
creased cell proliferation (p = 2.7E-04). There was a de-
creased expression of pro-inflammatory genes, which are
well-known MS associated genes, such as: CCL2, IL-
12RB1, and IL-23. In addition, canonical MS related IL-17
pathways, were found to be suppressed (p = 1.4E-03) with
genes such as: CCL2, MAPK11, MUC5B, TRAF3IP2 (be-
ing under expressed).
Fig. 2 Differential gene expression of RRMS IFN responders compared to untreated RRMS. a. Volcano plot - Each dot represents a gene, red dots
demonstrate positive fold change and blue negative fold change. Cut off line showing p-value level of 0.05 by Bonferroni multiple correction,
with 104 DEG’s above cut off line. b. Enrichment of IFN signaling pathway within RRMS IFN responders. Up-regulated genes are marked in red
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Classification of SPMS patients based on IFN induced
DEGs of RRMS clinical responders
Unsupervised hierarchical clustering of SPMS patients,
based on the 104 DEGs associated with IFN treated
RRMS patients, yielded two distinct patients clusters
(Fig. 3). One cluster, defined as ‘SPMS IFN transcrip-
tional responders’, consisted of 12 IFN treated patients
comprising 60 % of SPMS treated cohort. These SPMS
patients showed a similar transcriptional response profile
to that seen in the RRMS IFN treated cohort with an
agreement of 100 out of 104 genes, 85 genes being over-
expressed and 15 genes under-expressed, similarly in
both groups.
The second cluster of patients was characterized by a
lack of the IFN inducible transcriptional response, and
was comprised of 38 patients consisting of 8 SPMS IFN
treated patients (40 % of SPMS treated cohort), defined
as SPMS IFN transcriptional non-responders, and 30 un-
treated SPMS patients.
To further establish these findings an additional differ-
ential expression analysis examining SPMS transcrip-
tional IFN responders (n = 12) as compared to SPMS
untreated patients (n = 30) was performed, and 94 of the
104 DEGs were significantly differentially expressed. In
contrast, SPMS transcriptional non-responders (n = 8)
had no genes at all that were differentially expressed
from untreated SPMS patients. To assess if lack of IFN
transcriptional response is dependent on the presence of
anti-IFN antibodies, IFN NAB status was examined in
SPMS IFN treated transcriptional non–responders. In
75 % of these patients IFN NAB were found to be NAB
negative.
Association of IFN inducible transcriptional clusters with
clinical patient characteristics
We examined the demographic and clinical characteristics
of SPMS patients, which may account for transcriptional
differences between: IFN-treated SPMS transcriptional re-
sponders, non-responders and untreated SPMS patients
(Table 2). Notably, SPMS transcriptional responders had
significantly: 1. Shorter disease duration (12.9 ± 2.1 years vs.
19.0 ± 1.5 years in non-responders, p = 0.03, and 22.3 ±
2.8 years in untreated SPMS patients, p = 0.01); 2. Higher
annual EDSS progression rate from disease onset (0.6 ± 0.1
vs. 0.3 ± 0.1, p = 0.02 in non-responders); 3. Higher annual
relapse rate (0.8 ± 0.1 transcriptional responders vs. 0.4 ±
0.04 non-responders and 0.4 ± 0.04 untreated, p = 0.01);
4. Shorter time on IFN treatment (3.5 ± 0.8 years tran-
scriptional responders versus 6.4 ± 1.2 non-responders,
p = 0.05). These differences reflect that SPMS patients
that are transcriptional responders have a more aggressive
Fig. 3 Clustering of SPMS patients based on 104 DEGs. Heatmap depicting hierarchical clustering of SPMS patients according to expression of
104 DEGs, upregulated genes demonstrated in red and down regulated in blue. The left vertical panel presents treatment status of SPMS
patients: non treated -purple, IFN treated transcriptional responders- green, IFN treated transcriptional non-responders - yellow
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disease course as compared with transcriptional non-
responders.
Verification of IFN inducible IFI 44 and OAS1 by qRT-PCR
Verification was performed on an additional independ-
ent group of 27 IFN treated SPMS patients. We com-
pared 13 patients (age 52.7 ± 5.2 years, 8 females, EDSS
6.3 ± 0.2, disease duration 20.3 ± 2.2 years), characterized
by a high disease activity defined as continued disability
progression two years following sampling (EDSS increase
by 0.7 ± 0.1) with 14 patients (age 58.7 ± 2.3 years, 12 fe-
males, EDSS 6.0 ± 0.1, disease duration 22.0 ± 1.9) who
had low activity disease, defined as no progression of
EDSS two years following sampling. IFN NAB status was
similar between groups, each having 4 patients that were
positive for IFN NAB. Patients with higher disease activ-
ity had significantly higher expression levels of IFN in-
ducible IFI44 (3.5 ± 0.4 vs. 1.9 ± 0.4, p = 0.01) and OAS1
(4.4 ± 0.4 vs. 2.6 ± 0.5, p = 0.01) genes (Fig. 4).
Discussion
SPMS is a devastating progressive phase of MS, whereby
patients gradually develop permanent disability. Clinical
response to IFN treatment in SPMS patients is heteroge-
neous and overall IFN is unable to prevent disease pro-
gression. However, it has been reported that a subgroup
of SPMS patients with active disease, reflected by short
disease duration and high relapse rate prior to trans-
forming to the SP phase, exhibit better therapeutic re-
sponse to IFN treatment [9]. In the current study, we
further expanded this concept by demonstrating that
within our cohort of SPMS patients, 60 % characterized
by active disease had blood transcriptional signature of re-
sponse to IFN treatment similar to that of RRMS patients
that were good clinical responders to treatment. Our find-
ings, obtained by microarray gene expression technology,
were than verified with an independent cohort of patients,
by examining expression of key IFN- inducible genes by
qRT-PCR.
Table 2 Demographical and clinical characteristics of SPMS patients
Treated IFN transcriptional responders Treated IFN transcriptional non responders Untreated
N 12 8 30
Age (years) 52.4 ± 2.8 54.9 ± 1.5 51.3 ± 1.4
F (M) 10 (2) 6 (2) 18 (12)
Disease duration (years) 12.9 ± 2.1(*)(**) 22.3 ± 2.8 19.0 ± 1.5
EDSS 6.3 ± 0.2(**) 6.3 ± 0.3 7.2 ± 0.1
Time to EDSS 6 (years) 11.4 ± 2.0 13.5 ± 1.4 12.6 ± 1.3
Annual EDSS change 0.6 ± 0.1(*) 0.3 ± 0.1 0.4 ± 0.1
Relapse rate 0.8 ± 0.1(*)(**) 0.4 ± 0.04 0.4 ± 0.05
Treatment duration (years) 3.5 ± 0.8(*) 6.4 ± 1.2 NA
*p <0.05 between SPMS transcriptional responders vs. non-responders
**p < 0.05 between SPMS transcriptional responders vs. untreated
Fig. 4 qRT-PCR verification of key IFN inducible genes. Expression of IFN induced (a) IFI44 and (b) OAS1 in SPMS IFN treated patients
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Although in SPMS the dominant pathological element
is neurodegenerative, this is not to say that inflammation
is absent. In a large pathological study of the brain in
SPMS patients, it was shown that neurodegeneration is
associated with ongoing inflammation, and reduction of
the inflammatory process correlated to parallel reduction
in neurodegeneration [6]. These findings strengthen the
biological reasoning that identification of SPMS patients
with an active inflammatory component that could be
targeted by IFN is important for the selection of appro-
priate patients for treatment. Indeed, we found a subset
of SPMS patients, who have a natural history of disease
characterized by a more aggressive disease course even
prior to IFN treatment, that exhibit an RRMS like tran-
scriptional response to IFN treatment and therefore have
the minimum molecular requirement that can be trans-
lated to clinical responsiveness to IFN treatment. In con-
trast, SPMS patients (IFN transcriptional non responders),
who do not exhibit any molecular response to IFN treat-
ment, are less likely to show beneficial clinical response to
treatment.
The transcriptional signature we identified in RRMS
IFN treatment responders is in agreement with that seen
in previous studies [17, 26, 27]. This signature showed
high enrichment for IFN signaling and featured genes
related to immunoregulatory effects including Jak/STAT
signaling, antiviral activity, immune-regulation, cell sur-
vival and apoptosis, cell cycle control, and transcription
regulation. This signature is known to cause an anti-
inflammatory shift in expression of cytokines and che-
mokines, modulation of T cell adhesion and blood brain
barrier extravasation, and an overall reduction in acti-
vated T cells entering the brain [15].
The identified IFN transcriptional signature included
genes which have previously been shown to correlate
with the clinical effects of treatment in RRMS patients.
A study examining expression level of MxA, an IFN in-
duced gene, among 126 RRMS patients, showed that pa-
tients with lower expression of MxA had a higher rate of
relapses [28]. Another study of 77 RRMS patients, found
that patients with good clinical response to IFN showed
up regulated expression levels of 8 IFN induced genes
including IFIT1, IFIT3, IFI44, and OASL after two years
of treatment [18]. Two genome wide association studies
(GWAS) have been conducted in order to identify genetic
determinants of response to IFN beta treatment [29, 30].
These studies discovered a total of 23 significant single
nucleotide polymorphisms (SNP) associated with better
response to interferon, of which ADAR gene, involved in
post transcriptional modification of mRNA and suppres-
sion of type 1 interferon signaling, was also found to be
differentially expressed in our 104 DEG's signature of IFN
inducible profile. Interestingly, ADAR gene was one of the
few validated and confirmed SNPs in both of the previous
GWAS studies [31]. Our findings provide additional evi-
dence to support the role of ADAR gene on influencing
molecular response to IFN.
The relation between expression of IFN inducible
genes and clinical response to treatment, as observed in
RRMS patients, suggests that in SPMS patients as well,
the ability of inflammatory blood cells to have a tran-
scriptional response to IFN, as we observed in 60 % of
patients, is a necessary prerequisite for clinical response.
One possible explanation why 40 % of SPMS treated
patients in our cohort lack an IFN inducible transcrip-
tional signature is long treatment duration. Previous
studies, focusing on long term IFN treatment in RRMS,
had shown that patients may cease to express the IFN
related expression signature [27]. This is in agreement
with our currents findings demonstrating SPMS tran-
scriptional non-responders also had longer treatment
duration. Additionally, the production of IFN antibodies
could neutralize treatment effect causing a transcrip-
tional switch from IFN inducible to non-inducible signa-
ture. However, in our patient cohort this was not the
case, with a majority of our SPMS treated transcriptional
non responding patients negative IFN antibody status.
Conclusion
The present study is innovative in demonstrating the
concept that there is a subpopulation of IFN treated
SPMS patients, who have a transcriptional profile which
is similar to that identified in IFN treated clinically
responding RRMS patients. We believe this finding may
have therapeutic implications that can assist in future
tailoring of IFN treatment in SPMS patients.
Additional files
Additional file 1: Table S1. List of DEGs characterizing RRMS clinical
responders. (XLSX 17 kb)
Additional file 2: Table S2. List of DEGs characterizing SPMS untreated
vs. RRMS untreated patients. (XLSX 21 kb)
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